Business Wire

JSSI Accelerates Digital Strategy With TRAXXALL Acquisition

14.12.2021 18:55:00 EET | Business Wire | Press release

Share

Jet Support Services, Inc. (JSSI), the leading independent provider of maintenance support and financial services to the business aviation industry, today announced the acquisition of TRAXXALL. Founded in 2013, TRAXXALL provides software-as-a-service (“SaaS”) solutions for aircraft maintenance tracking, parts inventory management, and cloud-based software to enhance aircraft maintenance, repair and overhaul (MRO) workflow. Headquartered in Montreal, Canada, TRAXXALL has offices around the world.

TRAXXALL has quickly emerged as a significant player in the maintenance tracking market. Named by the Financial Times as one of the Americas’ fastest growing companies, TRAXXALL delivers software to help customers reduce aircraft downtime, improve data accuracy, and have comprehensive visibility over maintenance costs, parts inventory, and MRO operations.

“JSSI and TRAXXALL have a shared history of challenging the status quo and putting customers first,” said Neil Book, CEO of JSSI. “This business combination presents an exciting opportunity to deliver huge value to our customers and dramatically accelerate the growth trajectory for both companies.”

TRAXXALL’s global team will join JSSI’s growing SaaS division, which comprises previous acquisition SierraTrax, reporting to Ash Reddy, recently promoted to the position of chief operating officer at JSSI.

“We take great pride in our reputation in the business aviation market as a thought partner and maintenance advisor to a robust and diverse fleet of aircraft around the world,” said Reddy. “As we now combine TRAXXALL with JSSI’s core products and data, we are confident in our ongoing business mission to add tangible value for aircraft owners, operators, and maintenance facilities.”

“I am so incredibly proud of what the Traxxall team has achieved,” said Scott Henderson, CEO of TRAXXALL. “I could not think of a better long-term partner for our business than the team at JSSI.”

“JSSI’s values are firmly aligned with our own and will allow us to further develop and enhance our suite of products,” added Mark Steinbeck, president of TRAXXALL. “With direct access to JSSI’s data and capabilities, we will rapidly grow the maintenance tracking business alongside the SierraTrax brand and deliver advanced maintenance tracking solutions to a wider cross section of the business aviation community.”

In addition to its growing maintenance tracking software business, JSSI provides aircraft parts, engines and APUs to hundreds of operators across all makes and models through its JSSI Parts & Leasing business and offers a range of digital tools through Conklin & de Decker to help customers benchmark and compare aircraft ownership options with the most accurate performance and comparison data available. This move to develop the company’s maintenance tracking offering further establishes JSSI as the go-to source for business aviation intelligence and support for the entire aircraft life cycle.

GTCR, a leading private equity firm, is a majority investor in JSSI.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chiara Lawrance
clawrance@8020comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye